Boston Scientific Corporation (BSX)
- Previous Close
68.99 - Open
73.14 - Bid 73.48 x 900
- Ask 73.49 x 900
- Day's Range
72.55 - 74.39 - 52 Week Range
48.35 - 74.39 - Volume
6,059,561 - Avg. Volume
6,345,345 - Market Cap (intraday)
108.008B - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
68.67 - EPS (TTM)
1.07 - Earnings Date Apr 24, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
74.20
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
www.bostonscientific.comRecent News: BSX
Performance Overview: BSX
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BSX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BSX
Valuation Measures
Market Cap
101.41B
Enterprise Value
110.04B
Trailing P/E
64.48
Forward P/E
30.67
PEG Ratio (5yr expected)
1.82
Price/Sales (ttm)
7.09
Price/Book (mrq)
5.26
Enterprise Value/Revenue
7.73
Enterprise Value/EBITDA
31.93
Financial Highlights
Profitability and Income Statement
Profit Margin
11.18%
Return on Assets (ttm)
4.47%
Return on Equity (ttm)
8.58%
Revenue (ttm)
14.24B
Net Income Avi to Common (ttm)
1.57B
Diluted EPS (ttm)
1.07
Balance Sheet and Cash Flow
Total Cash (mrq)
865M
Total Debt/Equity (mrq)
48.99%
Levered Free Cash Flow (ttm)
1.88B
Research Analysis: BSX
Company Insights: BSX
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: BSX
The Argus Innovation Model Portfolio
The United States economy is full of innovation. It has to be. Manufacturing industries that dominated the economy decades ago - textiles, televisions, even automobiles to a large degree - have moved overseas, where labor and materials costs are lower. Yet the U.S. economy, even during the pandemic and the current period of high inflation, has expanded to record levels. If U.S. corporations weren't innovating, creating new products (such as vaccines and AI) and services (such as Zoom calls) and moving into new markets, the domestic economy would not be growing, and capital would not be flooding into the country. The current high level of the U.S. dollar relative to currencies around the world attests to the confidence that global investors have in the durable and innovative U.S. economy.
Analyst Report: Boston Scientific Corp.
Based in Marlborough, Massachusetts, Boston Scientific is a developer, manufacturer, and marketer of medical devices used in a range of interventional medical specialties, including interventional cardiology, peripheral interventions, vascular surgery, electrophysiology, oncology, endoscopy, urology, gynecology, and neuromodulation. The company is a component of the S&P 500.
RatingPrice TargetMarket Digest: BSX, PEP
That first quarter was one heck of a party -- and now we've had two consecutive quarters of strong gains. As well, there have been five months with gains and 18 out 22 weeks in which the S&P 500 (SPX) has moved higher. And that happened with barely a speck of price volatility. The S&P 500 rose 10.2% in Q1, the S&P 100 (OEX) was up 10.9%, the Nasdaq (IXIC) was up 9.1%, the Nasdaq 100 (NDX) was up 8.5%, the S&P MidCap 400 (MDY) was up 9.9%, and the Russell 2000 (IWM) was up 5%. Bonds sold off a bit, the 10-year was up 34 basis points, gold (GLD) was up 7.6%, WTI was up 16%, the U.S. Dollar Index was up 2.4%, and Bitcoin soared 65%.
Analyst Report: Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
RatingPrice Target